{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/legend-biotech-legn/",
 "dataUrl": "https://clearank.com/stock/legend-biotech-legn/data.json",
 "title": "Legend Biotech (LEGN) Stock Forecast & Price Target (2026)",
 "description": "Legend Biotech Corporation (LEGN) stock: Healthcare, Biotechnology. $3.7B market cap. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "Legend Biotech Corporation (LEGN)",
 "published": "2026-06-04T09:10:49+00:00",
 "modified": "2026-09-27T04:56:44.531+00:00",
 "generated": "2026-09-27T15:06:59.982Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "LEGN",
  "name": "Legend Biotech Corporation",
  "type": "American Depositary Receipt",
  "exchange": "NASDAQ",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Biotechnology",
  "country": "United States",
  "website": "https://www.legendbiotech.com"
 },
 "quote": {
  "price": 19.11,
  "previousClose": 19.06,
  "change": 0.05,
  "changePercent": 0.26,
  "open": 19.49,
  "high": 19.69,
  "low": 18.85,
  "volume": 1428100,
  "averageVolume": 2589190,
  "marketCap": 3716673572,
  "fiftyTwoWeekHigh": 37.5,
  "fiftyTwoWeekLow": 16.24,
  "marketOpen": false,
  "asOf": "2026-09-27T04:56:44.000Z"
 },
 "statistics": {
  "pe": -38.22,
  "eps": -0.5,
  "dividendYield": 0,
  "beta": 0.402,
  "priceToSales": 2.9232924,
  "priceToBook": 3.0113456,
  "revenueTtm": 1271399936,
  "grossMargin": 0.6454193548387097,
  "returnOnEquity": -0.080790006
 },
 "technicals": {
  "rsi": 32.81,
  "macd": -0.72,
  "sma50": 20.26,
  "sma200": 22.5,
  "rsiSignal": "Bearish",
  "trend": "Bearish",
  "pricePosition": "Bearish",
  "macdSignal": "Bearish",
  "rating": "Bearish"
 },
 "analysis": {
  "rating": "Hold",
  "score": 55,
  "consensus": "Hold",
  "fairValue": 19.11,
  "analystTarget": 48.5,
  "analystCount": 14,
  "wallStreetConsensus": "Strong Buy",
  "generatedAt": "2026-09-27T04:56:44.000Z",
  "priceAtAnalysis": 19.11,
  "volatility": {
   "daily": 3.25,
   "risk": "volatile"
  }
 },
 "tradePlan": {
  "bias": "Neutral",
  "conservativeEntry": 18.92,
  "aggressiveEntry": 19.11,
  "stopLoss": 17.59,
  "stopLossPercent": 7,
  "targets": [
   19.49,
   19.86,
   20.43
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 9.79,
    "base": 18.58,
    "upside90th": 35.27
   },
   {
    "year": 2028,
    "downside10th": 7.3,
    "base": 18.07,
    "upside90th": 44.72
   },
   {
    "year": 2029,
    "downside10th": 5.79,
    "base": 17.57,
    "upside90th": 53.3
   },
   {
    "year": 2030,
    "downside10th": 4.74,
    "base": 17.08,
    "upside90th": 61.54
   },
   {
    "year": 2031,
    "downside10th": 3.96,
    "base": 16.61,
    "upside90th": 69.61
   },
   {
    "year": 2032,
    "downside10th": 3.36,
    "base": 16.15,
    "upside90th": 77.6
   },
   {
    "year": 2033,
    "downside10th": 2.88,
    "base": 15.7,
    "upside90th": 85.57
   },
   {
    "year": 2034,
    "downside10th": 2.49,
    "base": 15.27,
    "upside90th": 93.54
   },
   {
    "year": 2035,
    "downside10th": 2.17,
    "base": 14.85,
    "upside90th": 101.52
   },
   {
    "year": 2036,
    "downside10th": 1.9,
    "base": 14.44,
    "upside90th": 109.53
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "LEGN Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$19.49",
    "Day Range": "$18.85 to $19.69",
    "Prev Close": "$19.06",
    "Volume": "1.43M",
    "52-Week Range": "$16.24 to $37.50",
    "Market Cap": "$3.72B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis On price-to-sales, the yardstick used here in place of P/E, LEGN trades at 2.92x, -21% versus the sector average of 3.70x."
   ]
  },
  {
   "id": "financials",
   "title": "LEGN Financial Performance"
  },
  {
   "id": "analysis",
   "title": "LEGN Analysis",
   "text": [
    "Legend Biotech Corporation's stock is currently trading below its 50-day and 200-day moving averages ($20.26 and $22.50), at $20.26 and $22.50 respectively, indicating a bearish trend. The Relative Strength Index (RSI) at 32.81 is in bearish territory, suggesting weakening momentum. Key support levels are not clearly defined given the current trend, while resistance may be found near the 50-day SMA. Volume has been below average recently, with the latest volume at 1.43 million compared to an average of 2.59 million, suggesting a lack of strong conviction from buyers. The chart structure implies further downside risk in the near term.",
    "Legend Biotech Corporation's revenue growth of 51.9% significantly outpaces the Healthcare sector median of 8.1%, indicating strong market adoption and expansion potential.",
    "The median analyst price target for LEGN is $48.5, representing a potential upside of 153.8% from the current price, driven by strong future growth estimates.",
    "Analysts project a significant turnaround in profitability, with next year's EPS estimated at $0.6831, a substantial increase from the current negative EPS.",
    "The stock is trading below its 50-day and 200-day moving averages ($20.26 and $22.50), and the RSI is in bearish territory, indicating a negative short-term trend.",
    "Insiders have been net sellers, with total sales of $331.5K, suggesting a degree of caution or profit-taking among management.",
    "Legend Biotech Corporation's outlook is cautiously optimistic, driven by strong projected revenue growth and a high Wall Street median price target of $48.5, implying over 150% upside. The company is expected to transition to profitability, with next year's EPS estimate at $0.6831 and a projected 106% growth rate. However, the current bearish technical trend and insider selling present near-term headwinds. A significant catalyst would be a sustained move above the 50-day and 200-day SMAs, coupled with positive earnings surprises and continued strong revenue expansion, to validate the optimistic analyst targets and shift the sentiment."
   ],
   "lists": {
    "ProTips": [
     "Legend Biotech Corporation's stock is trading below key moving averages, suggesting a potential for further downside before a significant recovery. Consider waiting for a confirmed technical breakout.",
     "Despite current losses, strong revenue growth and positive forward EPS estimates suggest a potential turnaround. Monitor upcoming earnings reports closely for signs of improving profitability.",
     "Insider selling, though moderate, warrants attention. While not a definitive sell signal, it suggests a degree of caution among management regarding near-term stock performance."
    ]
   },
   "catalysts": [
    {
     "type": "Bullish",
     "title": "Strong Revenue Growth Exceeds Sector Median",
     "text": "Legend Biotech Corporation's revenue growth of 51.9% significantly outpaces the Healthcare sector median of 8.1%, indicating strong market adoption and expansion potential.",
     "source": "Company Data"
    },
    {
     "type": "Bullish",
     "title": "High Wall Street Median Price Target",
     "text": "The median analyst price target for LEGN is $48.5, representing a potential upside of 153.8% from the current price, driven by strong future growth estimates.",
     "source": "Wall Street Summary"
    },
    {
     "type": "Bullish",
     "title": "Positive Forward EPS Estimates",
     "text": "Analysts project a significant turnaround in profitability, with next year's EPS estimated at $0.6831, a substantial increase from the current negative EPS.",
     "source": "Wall Street Summary"
    },
    {
     "type": "Bearish",
     "title": "Bearish Technical Momentum",
     "text": "The stock is trading below its 50-day and 200-day moving averages ($20.26 and $22.50), and the RSI is in bearish territory, indicating a negative short-term trend.",
     "source": "Technical Analysis"
    },
    {
     "type": "Bearish",
     "title": "Moderate Insider Selling Signal",
     "text": "Insiders have been net sellers, with total sales of $331.5K, suggesting a degree of caution or profit-taking among management.",
     "source": "Insider Summary"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "Legend Biotech Corporation's valuation appears stretched relative to its current profitability, with a negative P/E ratio due to its -0.50 EPS and a price-to-sales ratio of 2.92, which is below the sector median of 3.7. The company's return on equity is negative at -8.08%, contrasting with the sector median of 6.9%. Despite these profitability concerns, the company exhibits strong revenue growth at 51.9%, significantly exceeding the sector average of 8.1%. Its debt-to-equity ratio of 0.23 is healthy and below the sector median. The forward revenue growth estimates are also very strong, suggesting significant future expansion potential.",
    "Legend Biotech Corporation's most recent reported EPS was -0.50, which is a loss, and the company's profit margin is -7.20%. While specific quarterly earnings beats or misses are not detailed, the overall trend indicates ongoing losses despite substantial revenue growth. Forward EPS estimates for the next year are positive at $0.6831, suggesting an anticipated turnaround in profitability.",
    "The primary risks for Legend Biotech Corporation include its current unprofitability, evidenced by negative EPS and net profit margin, which could pressure its valuation. Insiders have been net sellers, indicating a degree of caution despite strong revenue growth. Also, the stock is trading below key technical indicators, suggesting potential for further downside momentum."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "3.72B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "N/A (Negative EPS)"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "-0.5000"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "0.00%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "37.50"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "16.24"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bearish RSI Bearish SMA Cross Bearish Price vs SMA Bearish MACD Bearish Moving averages show a lagging Death Cross (50-day: $20.26, 200-day: $22.50), price is trading below the 50-day SMA."
   ],
   "facts": {
    "RSI": "Bearish",
    "SMA Cross": "Bearish",
    "Price vs SMA": "Bearish",
    "MACD": "Bearish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "32.81"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "-0.72"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "20.26"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "22.50"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.15",
    "Correlation with Nasdaq 100 (QQQ)": "+0.14",
    "Correlation with Bitcoin (BTC)": "+0.09",
    "Correlation with Gold (XAU)": "+0.09"
   }
  },
  {
   "id": "trade-plans",
   "title": "LEGN Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Enter now if confident",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (32.8) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$19.49",
    "TARGET 2": "$19.86",
    "TARGET 3": "$20.43",
    "STOP LOSS": "$17.59"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "-5.55%",
    "Average Feb return": "+0.28%",
    "Average Mar return": "-0.97%",
    "Average Apr return": "+10.82%",
    "Average May return": "+2.33%",
    "Average Jun return": "+14.76%",
    "Average Jul return": "-2.94%",
    "Average Aug return": "-0.05%",
    "Average Sep return": "-2.21%",
    "Average Oct return": "+1.25%",
    "Average Nov return": "-2.44%",
    "Average Dec return": "-9.33%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "3.25%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in LEGN in June 2020 would be worth about $5,165 today, compared with about $24,155 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in LEGN today could grow to about $7,555 by 2036 in the base case, with a bull case near $57,315 and a bear case around $996. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "LEGN Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $17.08 for LEGN by 2030 in the base case, from $19.11 today (0.9x over 4 years). The downside path ends near $4.74. These are outcomes of a Monte Carlo simulation run on LEGN's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using LEGN's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "LEGN simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$9.79",
        "$18.58",
        "$35.27"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$7.30",
        "$18.07",
        "$44.72"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$5.79",
        "$17.57",
        "$53.30"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$4.74",
        "$17.08",
        "$61.54"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$3.96",
        "$16.61",
        "$69.61"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$3.36",
        "$16.15",
        "$77.60"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$2.88",
        "$15.70",
        "$85.57"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$2.49",
        "$15.27",
        "$93.54"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$2.17",
        "$14.85",
        "$102"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$1.90",
        "$14.44",
        "$110"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "LLY Eli Lilly and Company NYSE $1,183.46 +0.13%",
     "url": "https://clearank.com/stock/eli-lilly-lly/"
    },
    {
     "text": "RMD ResMed Inc. NYSE $222.00 +0.05%",
     "url": "https://clearank.com/stock/rmd-stock-analysis/"
    },
    {
     "text": "DXCM DexCom Inc. NASDAQ $86.62 -0.97%",
     "url": "https://clearank.com/stock/dxcm-stock-analysis/"
    },
    {
     "text": "MOH Molina Healthcare Inc. NYSE $190.86 -1.27%",
     "url": "https://clearank.com/stock/moh-stock-analysis/"
    },
    {
     "text": "CRNX Crinetics Pharmaceuticals, Inc. NASDAQ $84.95 +0.00%",
     "url": "https://clearank.com/stock/crinetics-pharmaceuticals-crnx/"
    },
    {
     "text": "NTRA Natera, Inc. NASDAQ $412.56 +0.92%",
     "url": "https://clearank.com/stock/natera-ntra/"
    },
    {
     "text": "REGN Regeneron Pharmaceuticals, Inc. NASDAQ $788.04 -1.00%",
     "url": "https://clearank.com/stock/regeneron-regn/"
    },
    {
     "text": "BMY Bristol-Myers Squibb Company NYSE $62.86 +2.21%",
     "url": "https://clearank.com/stock/bristol-myers-squibb-bmy/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Popular Comparisons",
   "links": [
    {
     "text": "BTC/USD vs SOL/USD Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/btc-vs-sol/"
    },
    {
     "text": "STZ vs TAP Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/stz-vs-tap/"
    },
    {
     "text": "CCJ vs CEG Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/ccj-vs-ceg/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "LEGN Insider Trading Analysis",
   "facts": {
    "Bought": "None",
    "Sold": "$331.5K",
    "Insiders": "3",
    "Avg Transaction": "$165.8K"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in LEGN",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Jun 30, 2026",
       "cells": [
        "CASEY PATRICK JOHN PH.D. Director",
        "Sell",
        "6.0K",
        "$173.3K"
       ]
      },
      {
       "label": "Jun 25, 2026",
       "cells": [
        "HUANG YING Chief Executive Officer",
        "Sell",
        "5.6K",
        "$158.2K"
       ]
      },
      {
       "label": "Aug 14, 2026",
       "cells": [
        "BASH ALAN Chief Executive Officer",
        "Grant",
        "4.9K",
        "-"
       ]
      },
      {
       "label": "Jun 30, 2026",
       "cells": [
        "HUANG YING Chief Executive Officer",
        "Grant",
        "3.4K",
        "-"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=Legend+Biotech+Corporation&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "What is Legend Biotech Corporation's stock price forecast for 2030?",
   "answer": "Legend Biotech Corporation's stock price forecast for 2030, based on Monte Carlo simulations, projects a base case of $17.08, a downside scenario of $4.74, and an upside scenario of $61.54. These figures represent statistical outcomes and are not guarantees."
  },
  {
   "question": "Is Legend Biotech Corporation stock a buy right now?",
   "answer": "Legend Biotech Corporation is currently rated a 'Hold' with a consensus score of 55. While Wall Street has a strong buy consensus and a median price target of $48.5, the stock is trading below key moving averages and insiders have been net sellers."
  },
  {
   "question": "What is Legend Biotech Corporation's current technical outlook?",
   "answer": "The technical outlook for Legend Biotech Corporation is bearish, with the stock trading below its 50-day and 200-day moving averages ($20.26 and $22.50) and exhibiting bearish RSI momentum. Volume has also been below average, indicating a lack of buying conviction."
  },
  {
   "question": "How does Legend Biotech Corporation compare to its sector averages?",
   "answer": "Legend Biotech Corporation significantly outperforms its sector in revenue growth (51.9% vs. 8.1% median) but lags in profitability metrics like ROE (-8.08% vs. 6.9% median). Its P/E is negative, while the sector median is 31.9."
  },
  {
   "question": "What are the key risks facing Legend Biotech Corporation?",
   "answer": "Key risks include the company's current unprofitability, insider net selling activity, and a bearish technical trend. These factors counterbalance the strong revenue growth and optimistic analyst price targets."
  },
  {
   "question": "What is the Wall Street consensus on Legend Biotech Corporation?",
   "answer": "Wall Street analysts maintain a 'Strong Buy' consensus for Legend Biotech Corporation, with 5 strong buys and 4 buys out of 14 analysts. The median price target is $48.5, indicating a significant upside potential from the current price."
  },
  {
   "question": "What is Legend Biotech Corporation's profitability status?",
   "answer": "Legend Biotech Corporation is currently loss-making, reporting a negative EPS of -0.50 and a net profit margin of -7.20%. However, forward EPS estimates for next year are positive, suggesting an anticipated improvement in profitability."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "LLY",
    "name": "Eli Lilly and Company NYSE",
    "price": "$1,183.46",
    "change": "+0.13%",
    "url": "https://clearank.com/stock/eli-lilly-lly/"
   },
   {
    "ticker": "RMD",
    "name": "ResMed Inc. NYSE",
    "price": "$222.00",
    "change": "+0.05%",
    "url": "https://clearank.com/stock/rmd-stock-analysis/"
   },
   {
    "ticker": "DXCM",
    "name": "DexCom Inc. NASDAQ",
    "price": "$86.62",
    "change": "-0.97%",
    "url": "https://clearank.com/stock/dxcm-stock-analysis/"
   },
   {
    "ticker": "MOH",
    "name": "Molina Healthcare Inc. NYSE",
    "price": "$190.86",
    "change": "-1.27%",
    "url": "https://clearank.com/stock/moh-stock-analysis/"
   },
   {
    "ticker": "CRNX",
    "name": "Crinetics Pharmaceuticals, Inc. NASDAQ",
    "price": "$84.95",
    "change": "+0.00%",
    "url": "https://clearank.com/stock/crinetics-pharmaceuticals-crnx/"
   },
   {
    "ticker": "NTRA",
    "name": "Natera, Inc. NASDAQ",
    "price": "$412.56",
    "change": "+0.92%",
    "url": "https://clearank.com/stock/natera-ntra/"
   },
   {
    "ticker": "REGN",
    "name": "Regeneron Pharmaceuticals, Inc. NASDAQ",
    "price": "$788.04",
    "change": "-1.00%",
    "url": "https://clearank.com/stock/regeneron-regn/"
   },
   {
    "ticker": "BMY",
    "name": "Bristol-Myers Squibb Company NYSE",
    "price": "$62.86",
    "change": "+2.21%",
    "url": "https://clearank.com/stock/bristol-myers-squibb-bmy/"
   }
  ],
  "comparisons": [
   {
    "ticker": "BTC/USD vs SOL/USD Comparison",
    "name": "",
    "url": "https://clearank.com/compare/btc-vs-sol/"
   },
   {
    "ticker": "STZ vs TAP Comparison",
    "name": "",
    "url": "https://clearank.com/compare/stz-vs-tap/"
   },
   {
    "ticker": "CCJ vs CEG Comparison",
    "name": "",
    "url": "https://clearank.com/compare/ccj-vs-ceg/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "SPG",
    "text": "Simon Property Group Inc.",
    "url": "https://clearank.com/stock/spg-stock-analysis/"
   },
   {
    "ticker": "JCI",
    "text": "Johnson Controls International",
    "url": "https://clearank.com/stock/jci-stock-analysis/"
   },
   {
    "ticker": "BLDR",
    "text": "Builders FirstSource Inc",
    "url": "https://clearank.com/stock/bldr-stock-analysis/"
   },
   {
    "ticker": "EIS",
    "text": "iShares MSCI Israel ETF",
    "url": "https://clearank.com/etf/eis-etf-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "ETHFI/USD",
    "text": "↓ 13.68%",
    "url": "https://clearank.com/crypto/ethfi-usd-crypto-analysis/"
   },
   {
    "ticker": "TON/USD",
    "text": "↑ 12.10%",
    "url": "https://clearank.com/crypto/toncoin-ton-usd/"
   },
   {
    "ticker": "SUI/USD",
    "text": "↑ 11.97%",
    "url": "https://clearank.com/crypto/sui-sui-usd/"
   },
   {
    "ticker": "KAS/USD",
    "text": "↑ 11.85%",
    "url": "https://clearank.com/crypto/kaspa-kas-usd/"
   },
   {
    "ticker": "RENDER/USD",
    "text": "↑ 10.19%",
    "url": "https://clearank.com/crypto/render-render-usd/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "FBRX",
    "text": "Forte",
    "url": "https://clearank.com/stock/fbrx-stock-analysis/"
   },
   {
    "ticker": "IONS",
    "text": "Ionis",
    "url": "https://clearank.com/stock/ions-stock-analysis/"
   },
   {
    "ticker": "MRNA",
    "text": "Moderna, Inc.",
    "url": "https://clearank.com/stock/moderna-mrna/"
   },
   {
    "ticker": "REGN",
    "text": "Regeneron Pharmaceuticals",
    "url": "https://clearank.com/stock/regeneron-regn/"
   },
   {
    "ticker": "REPL",
    "text": "Replimune",
    "url": "https://clearank.com/stock/repl-stock-analysis/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "alternateName": "CleaRank Financial AI",
     "url": "https://clearank.com",
     "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis, trade plans and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free; CleaRank is paid for by subscriptions to its trading workbench (Pro $29 a month, Ultra $59 a month), which combines a live trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. Some free content contains partner links, which are disclosed and do not affect ratings.",
     "slogan": "Clear data. Honest analysis.",
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "image": {
      "@id": "https://clearank.com/#logo"
     },
     "sameAs": [
      "https://x.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank",
      "https://t.me/clearank"
     ],
     "email": "info@clearank.com",
     "contactPoint": [
      {
       "@type": "ContactPoint",
       "contactType": "customer support",
       "email": "info@clearank.com",
       "url": "https://clearank.com/contact/",
       "availableLanguage": "en"
      }
     ],
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     },
     "knowsAbout": [
      "stock analysis",
      "ETF analysis",
      "cryptocurrency analysis",
      "forex trading",
      "trading simulation",
      "trade journaling",
      "position sizing",
      "risk management",
      "prop firm challenges",
      "online broker regulation"
     ],
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "ethicsPolicy": "https://clearank.com/editorial-code/",
     "ownershipFundingInfo": "https://clearank.com/about-us/",
     "owns": {
      "@id": "https://clearank.com/#app"
     },
     "founder": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/06/legend-biotech-legn.png",
     "url": "https://clearank.com/wp-content/uploads/2026/06/legend-biotech-legn.png",
     "width": "1280",
     "height": "720",
     "caption": "Legend Biotech (LEGN) stock price analysis chart for June 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/legend-biotech-legn/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/legend-biotech-legn/",
        "name": "Legend Biotech (LEGN) Stock Price Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/legend-biotech-legn/#webpage",
     "url": "https://clearank.com/stock/legend-biotech-legn/",
     "name": "Legend Biotech (LEGN) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-06-04T09:10:49+00:00",
     "dateModified": "2026-09-27T04:56:44+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/06/legend-biotech-legn.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/legend-biotech-legn/#breadcrumb"
     },
     "reviewedBy": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "Person",
     "@id": "https://clearank.com/writer/shaundavidb/#person",
     "name": "Shaun David",
     "jobTitle": "Co-Founder",
     "url": "https://clearank.com/writer/shaundavidb/",
     "image": "https://clearank.com/media/uploads/2025/01/Shaun-David-Author-Image-.jpeg",
     "sameAs": [
      "https://www.linkedin.com/in/shaun-david-697b5817a/"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     }
    },
    {
     "@type": "Article",
     "@id": "https://clearank.com/stock/legend-biotech-legn/#richSnippet",
     "headline": "Legend Biotech (LEGN) Stock Forecast & Price Target (2026)",
     "name": "Legend Biotech (LEGN) Stock Forecast & Price Target (2026)",
     "description": "Legend Biotech Corporation (LEGN) stock: Healthcare, Biotechnology. $3.7B market cap. AI rating, technicals, 2030 forecast and trade plans.",
     "datePublished": "2026-06-04T09:10:49+00:00",
     "dateModified": "2026-09-27T04:56:44+00:00",
     "author": {
      "@id": "https://clearank.com/#organization"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "about": {
      "@type": "Corporation",
      "name": "Legend Biotech Corporation",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "LEGN"
       },
       {
        "@type": "PropertyValue",
        "propertyID": "exchange",
        "value": "NASDAQ"
       }
      ],
      "description": "Legend Biotech Corporation ADR is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing cell therapies for oncology and other serious diseases. The company’s work centers on advanced immunotherapy platforms, including chimeric antigen receptor T-cell appr",
      "tickerSymbol": "LEGN",
      "sameAs": "https://www.legendbiotech.com"
     },
     "isPartOf": {
      "@id": "https://clearank.com/stock/legend-biotech-legn/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/06/legend-biotech-legn.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/legend-biotech-legn/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "What is Legend Biotech Corporation's stock price forecast for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Legend Biotech Corporation's stock price forecast for 2030, based on Monte Carlo simulations, projects a base case of $17.08, a downside scenario of $4.74, and an upside scenario of $61.54. These figures represent statistical outcomes and are not guarantees."
     }
    },
    {
     "@type": "Question",
     "name": "Is Legend Biotech Corporation stock a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Legend Biotech Corporation is currently rated a 'Hold' with a consensus score of 55. While Wall Street has a strong buy consensus and a median price target of $48.5, the stock is trading below key moving averages and insiders have been net sellers."
     }
    },
    {
     "@type": "Question",
     "name": "What is Legend Biotech Corporation's current technical outlook?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The technical outlook for Legend Biotech Corporation is bearish, with the stock trading below its 50-day and 200-day SMAs and exhibiting bearish RSI momentum. Volume has also been below average, indicating a lack of buying conviction."
     }
    },
    {
     "@type": "Question",
     "name": "How does Legend Biotech Corporation compare to its sector averages?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Legend Biotech Corporation significantly outperforms its sector in revenue growth (51.9% vs. 8.1% median) but lags in profitability metrics like ROE (-8.08% vs. 6.9% median). Its P/E is negative, while the sector median is 31.9."
     }
    },
    {
     "@type": "Question",
     "name": "What are the key risks facing Legend Biotech Corporation?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Key risks include the company's current unprofitability, insider net selling activity, and a bearish technical trend. These factors counterbalance the strong revenue growth and optimistic analyst price targets."
     }
    },
    {
     "@type": "Question",
     "name": "What is the Wall Street consensus on Legend Biotech Corporation?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Wall Street analysts maintain a 'Strong Buy' consensus for Legend Biotech Corporation, with 5 strong buys and 4 buys out of 14 analysts. The median price target is $48.5, indicating a significant upside potential from the current price."
     }
    },
    {
     "@type": "Question",
     "name": "What is Legend Biotech Corporation's profitability status?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Legend Biotech Corporation is currently loss-making, reporting a negative EPS of -0.50 and a net profit margin of -7.20%. However, forward EPS estimates for next year are positive, suggesting an anticipated improvement in profitability."
     }
    }
   ]
  }
 ]
}